✦ LIBER ✦

CHOP + ibritumomab tiuxetan beneficial in DLBCL in elderly

Book ID: 120844186
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2008
Weight: 120 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200816290-00023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radioimmunotherapy with ibritumomab tiux

Radioimmunotherapy with ibritumomab tiuxetan beneficial in NHL

📂 Article 📅 2002 🏛 Adis International Limited (now part of Wolters Kl ⚖ 138 KB

Ibritumomab tiuxetan launched in the UK

📂 Article 📅 2004 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Yttrium 90 ibritumomab tiuxetan in lymph

Yttrium 90 ibritumomab tiuxetan in lymphoma

✍ Cheung, Matthew C.; Haynes, Adam E.; Stevens, Adrienne; Meyer, Ralph M.; Imrie, 📂 Article 📅 2006 🏛 Informa plc 🌐 English ⚖ 147 KB

R-CHOP economically dominant over CHOP i

R-CHOP economically dominant over CHOP in DLBCL

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 143 KB

Ibritumomab tiuxetan improves conversion

Ibritumomab tiuxetan improves conversion rate in NHL

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 138 KB

Yttrium-90 ibritumomab tiuxetan radioimm

Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome

✍ Apostolia-Maria Tsimberidou; James L. Murray; Susan O'Brien; William G. Wierda; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

## Abstract ## BACKGROUND ^90^Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with lymphoma. The aim of the current analysis was to evaluate retrospectively the efficacy and safety of ^90^Y ibritumomab tiuxetan in patients wit